Patients with early-stage, node-negative, hormone receptor (HR)-positive, HER2- negative breast cancer who have a high risk of recurrence based on the OncotypeDX genomic test had better outcomes when ...

Key Leadership Appointments Bring New Skills and Capabilities to Organization EMERYVILLE, Calif., Dec. 13, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna) ...

Verition Fund Management LLC lowered its stake in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 66.0% in the third ...

AIDS Resource Alliance Inc. was recently selected as a second-year grant awardee of the AstraZeneca Foundation’s Creating Health Access for Next Generation Equity (CHANGE) program, which aims to ...

The ZEST clinical trial, designed to evaluate niraparib (Zejula) for the prevention of breast cancer recurrence in patients with circulating tumor DNA (ctDNA), failed to accrue enough patients ...

At 24 months, endocrine therapy appeared to have a more negative effect on HRQOL as measured by the global health status (GHS ...

The AstraZeneca PLC ADR AZN dropped 0.54% to $66.58 Friday, on what proved to be an all-around mixed trading session for the ...

Move over, AI. There's another fast-moving technology that's expected to generate massive financial gains in the second half of the 2020s. Quantum computing's reputation is growing as a tech ...

Researchers presented data from trials of HER2-targeted therapies from Jiangsu Hengrui Medicine, Jazz Pharma, Roche, and RemeGen.

NEW YORK, NY / ACCESSWIRE / December 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ...

At least 29 patent suits were filed in the District of New Jersey in November, reflecting a jump from the rate of 18 suits ...

Action is the latest following Baldwin’s investigation into the extremely high prices these companies charge for inhalers ...